Delving into the Latest Updates on Abacavir/Lamivudine/Lopinavir/Ritonavir with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Lopinav

Target

HIV-1 pol x RT

Mechanism

HIV-1 pol inhibitors(Human immunodeficiency virus type 1 protease inhibitors), RT inhibitors(Reverse transcriptase inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication

HIV Infections

Inactive Indication-

Originator Organization

Cipla Ltd.

Active Organization

Cipla Ltd.

Drugs for Neglected Diseases initiative

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC14H20N6O5S

InChIKeyMBFKCGGQTYQTLR-SCYNACPDSA-N

CAS Registry188062-50-2

View All Structures (4)

A phase I/II, open label, randomized crossover pharmacokinetic, safety and acceptability study of the Abacavir/Lamivudine/ Lopinavir/Ritonavir (30/15/ 40/10mg ;4-in-1) Fixed-Dose Combination vs. Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg tablets) in HIV infected Children.
The study is intended to support the adoption of the 4-in-1 by healthcare providers and will provide data that may support its registration in certain countries. The study will be carried out in HIV-infected children in Uganda weighing 3 to 25 kg (inclusive) and unable to swallow tablets and will provide supportive clinical data on the pharmacokinetics, safety, tolerability and acceptability of the 4-in-1.

Start Date04 Jun 2019

Sponsor / Collaborator

Drugs for Neglected Diseases initiative

[+4]

NCT01125696 / CompletedPhase 2IIT

Maternal Tenofovir-containing Combination Drug Regimen During the Second and Third Trimesters of Pregnancy for Prevention of Mother-to-child Transmission of HIV and HBV in HIV-HBV Co-infected Mothers

The purpose of this study is to compare a regimen of tenofovir/lamivudine/lopinavir-ritonavir to the WHO-recommended and locally practiced standard of care regimen consisting of zidovudine/lamivudine/lopinavir-ritonavir during the second and third trimesters of pregnancy in HIV and HBV co-infected women. This is a phase II study evaluating the safety of the test regimen in pregnant women and their newborns. While the study is not powered to examine efficacy, preliminary estimates of transmission of HIV and HBV to the infants and of the rate of resistance development will be obtained.

Start Date01 May 2012

Sponsor / Collaborator

Centers for Disease Control & Prevention

100 Clinical Results associated with Abacavir/Lamivudine/Lopinavir/Ritonavir

Login to view more data

100 Translational Medicine associated with Abacavir/Lamivudine/Lopinavir/Ritonavir

Login to view more data

100 Patents (Medical) associated with Abacavir/Lamivudine/Lopinavir/Ritonavir

Login to view more data

100 Deals associated with Abacavir/Lamivudine/Lopinavir/Ritonavir

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 2	-	Cipla Ltd.	-
HIV Infections	Phase 2	-	Drugs for Neglected Diseases initiative	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


PETITE study (IAS2021)	Not Applicable	-	-	Abacavir/lamivudine/lopinavir/ritonavir (4-in-1)	mtpcswfqga(lpokiqqqdc) = slfeqdankj opuegyacly (mxoyjimfss ) View more	-	01 Jan 2021
IAS2011	Not Applicable	HIV Infections	43	Abacavir/lamivudine fixed-dose combination with ritonavir-boosted Darunavir	qijsylcghz(rggulohedu) = dqpiryjlum nbkedypcgo (yauvsywxgu )	-	01 Jan 2011
IAS2010	Not Applicable	AIDS-related Kaposi Sarcoma	23	Co-formulated abacavir/lamivudine/zidovudine	iqjvdndobk(wvepuscahg) = fawefhupla mcpqqnzxoc (ekhdbwjzhc )	-	01 Jan 2010
IAS2010	Not Applicable	AIDS-related Kaposi Sarcoma	23	Co-formulated abacavir/lamivudine plus co-formulated lopinavir/ritonavir	iqjvdndobk(wvepuscahg) = gwjmuzmnvz mcpqqnzxoc (ekhdbwjzhc )	-	01 Jan 2010